Compare FRPT & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRPT | STOK |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2014 | 2019 |
| Metric | FRPT | STOK |
|---|---|---|
| Price | $50.00 | $29.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 10 |
| Target Price | ★ $76.94 | $39.20 |
| AVG Volume (30 Days) | ★ 1.9M | 475.5K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 183.87 | 92.73 |
| EPS | ★ 0.91 | N/A |
| Revenue | ★ $1,102,015,000.00 | $184,420,000.00 |
| Revenue This Year | $11.34 | N/A |
| Revenue Next Year | $9.13 | $77.49 |
| P/E Ratio | $54.79 | ★ N/A |
| Revenue Growth | 13.01 | ★ 404.50 |
| 52 Week Low | $46.45 | $10.64 |
| 52 Week High | $86.00 | $40.22 |
| Indicator | FRPT | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 38.78 | 37.50 |
| Support Level | $47.59 | $28.02 |
| Resistance Level | $56.73 | $35.11 |
| Average True Range (ATR) | 2.26 | 1.35 |
| MACD | 0.52 | -0.06 |
| Stochastic Oscillator | 51.82 | 23.56 |
Freshpet produces and sells premium fresh pet food through its company-owned refrigerators placed in grocery, mass and club, pet specialty, and natural stores. Freshpet primarily targets dogs (likely representing well north of 90% of sales), with cats and treats nascent contributors. Geographically, the company's home US market, where all its food is produced, accounts for nearly all of sales, with exports to Canada, the United Kingdom, and other European countries being very small contributors.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.